Heart failure (HF) with preserved ejection fraction (HFpEF) is a complex and increasingly prevalent syndrome, representing nearly half of all HF cases. Characterized by symptoms of HF despite a normal ...

Advances in hypertension as reported at ACC 2025 include two new therapies that achieve significant blood pressure (BP) reduction, and a comparison of renal denervation methods for resistant BP.

TRYVIO (aprocitentan) in the US and JERAYGO in Europe present significant market potential as novel therapies for patients with hypertension inadequately controlled by existing treatments. TRYVIO ...

DelveInsight's "TRYVIO/JERAYGO Market Size, Forecast, and Market Insight Report" highlights the details around TRYVIO/JERAYGO ...